Search alternatives:
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
601
Micromorphological impact of WSWE treatment on <i>S</i>. <i>globosa</i> cells.
Published 2022Subjects: -
602
-
603
WSWE treatment reduced total ergosterol amount in <i>S</i>. <i>globosa</i> cells.
Published 2022Subjects: -
604
-
605
-
606
-
607
-
608
-
609
-
610
-
611
-
612
DataSheet_2_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx
Published 2023“…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
-
613
DataSheet_1_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx
Published 2023“…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
-
614
-
615
The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution.
Published 2013“…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”
-
616
-
617
-
618
-
619
-
620